CLSI Announces Guidelines for Newborn Screening for Cystic Fibrosis
The abbreviated Wilson and Jungner criteria1 for an inheritable disorder to be considered for testing include an acceptable prevalence in the population, serious medical complications if not treated before symptoms arise, the potential for successful treatment, the availability of technology to scre...
Gespeichert in:
| Veröffentlicht in: | Laboratory medicine 2012-05, Vol.43 (4), p.31-32 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 32 |
|---|---|
| container_issue | 4 |
| container_start_page | 31 |
| container_title | Laboratory medicine |
| container_volume | 43 |
| creator | Hoffman, Gary L |
| description | The abbreviated Wilson and Jungner criteria1 for an inheritable disorder to be considered for testing include an acceptable prevalence in the population, serious medical complications if not treated before symptoms arise, the potential for successful treatment, the availability of technology to screen hundreds of specimens daily, and cost favorability (ie, the cost of detection by screening is significantly less than a clinical diagnosis). Newborn screening for cystic fibrosis (CF) meets these requirements and has been included in the 30 core disorders, recommended by the US Secretary of Health and Human Services, for which all state newborn screening programs should screen. |
| doi_str_mv | 10.1309/LM2AIVMAI9TR6JQI |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1020639451</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2688712671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c181i-ef9920416a0fa818442fe6a5250ebbb137bb8f19c145d90a0ac3a690770222093</originalsourceid><addsrcrecordid>eNpdkEtPwzAQhC0EEqFw5xiJc2D9SBwfo4i2QSkIWrhGtmsjV8UpdiPUf0-gnDjt7ujTzmgQusZwiymIu3ZBquZtUTVi9VI8PDcnKMGC0YxzCqcoAQCe5UD4ObqIcTOeTBQkQXXdLpu08r4fvDYxnQ1ubbbOj6vtQ_povlQffLrUwRjv_PuvWh_i3ul06lToo4uX6MzKbTRXf3OCXqf3q3qetU-zpq7aTOMSu8xYIQgwXEiwssQlY8SaQuYkB6OUwpQrVVosNGb5WoAEqaksBHAOhBAQdIJujn93of8cTNx3m34IfrTsMBAoqGA5Hik4UnoMF4Ox3S64DxkOI9T9VNX9r4p-A0JXW6U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1020639451</pqid></control><display><type>article</type><title>CLSI Announces Guidelines for Newborn Screening for Cystic Fibrosis</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Hoffman, Gary L</creator><creatorcontrib>Hoffman, Gary L</creatorcontrib><description>The abbreviated Wilson and Jungner criteria1 for an inheritable disorder to be considered for testing include an acceptable prevalence in the population, serious medical complications if not treated before symptoms arise, the potential for successful treatment, the availability of technology to screen hundreds of specimens daily, and cost favorability (ie, the cost of detection by screening is significantly less than a clinical diagnosis). Newborn screening for cystic fibrosis (CF) meets these requirements and has been included in the 30 core disorders, recommended by the US Secretary of Health and Human Services, for which all state newborn screening programs should screen.</description><identifier>ISSN: 0007-5027</identifier><identifier>EISSN: 1943-7730</identifier><identifier>DOI: 10.1309/LM2AIVMAI9TR6JQI</identifier><language>eng</language><publisher>Chicago: Oxford University Press</publisher><subject>Babies ; Colleges & universities ; Committees ; Cystic fibrosis ; Deoxyribonucleic acid ; DNA ; Medical screening ; Mutation ; Newborn babies ; Public health ; Quality control</subject><ispartof>Laboratory medicine, 2012-05, Vol.43 (4), p.31-32</ispartof><rights>Copyright American Society for Clinical Pathology May/Jun 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c181i-ef9920416a0fa818442fe6a5250ebbb137bb8f19c145d90a0ac3a690770222093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Hoffman, Gary L</creatorcontrib><title>CLSI Announces Guidelines for Newborn Screening for Cystic Fibrosis</title><title>Laboratory medicine</title><description>The abbreviated Wilson and Jungner criteria1 for an inheritable disorder to be considered for testing include an acceptable prevalence in the population, serious medical complications if not treated before symptoms arise, the potential for successful treatment, the availability of technology to screen hundreds of specimens daily, and cost favorability (ie, the cost of detection by screening is significantly less than a clinical diagnosis). Newborn screening for cystic fibrosis (CF) meets these requirements and has been included in the 30 core disorders, recommended by the US Secretary of Health and Human Services, for which all state newborn screening programs should screen.</description><subject>Babies</subject><subject>Colleges & universities</subject><subject>Committees</subject><subject>Cystic fibrosis</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Medical screening</subject><subject>Mutation</subject><subject>Newborn babies</subject><subject>Public health</subject><subject>Quality control</subject><issn>0007-5027</issn><issn>1943-7730</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkEtPwzAQhC0EEqFw5xiJc2D9SBwfo4i2QSkIWrhGtmsjV8UpdiPUf0-gnDjt7ujTzmgQusZwiymIu3ZBquZtUTVi9VI8PDcnKMGC0YxzCqcoAQCe5UD4ObqIcTOeTBQkQXXdLpu08r4fvDYxnQ1ubbbOj6vtQ_povlQffLrUwRjv_PuvWh_i3ul06lToo4uX6MzKbTRXf3OCXqf3q3qetU-zpq7aTOMSu8xYIQgwXEiwssQlY8SaQuYkB6OUwpQrVVosNGb5WoAEqaksBHAOhBAQdIJujn93of8cTNx3m34IfrTsMBAoqGA5Hik4UnoMF4Ox3S64DxkOI9T9VNX9r4p-A0JXW6U</recordid><startdate>201205</startdate><enddate>201205</enddate><creator>Hoffman, Gary L</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201205</creationdate><title>CLSI Announces Guidelines for Newborn Screening for Cystic Fibrosis</title><author>Hoffman, Gary L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c181i-ef9920416a0fa818442fe6a5250ebbb137bb8f19c145d90a0ac3a690770222093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Babies</topic><topic>Colleges & universities</topic><topic>Committees</topic><topic>Cystic fibrosis</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Medical screening</topic><topic>Mutation</topic><topic>Newborn babies</topic><topic>Public health</topic><topic>Quality control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoffman, Gary L</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Laboratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoffman, Gary L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CLSI Announces Guidelines for Newborn Screening for Cystic Fibrosis</atitle><jtitle>Laboratory medicine</jtitle><date>2012-05</date><risdate>2012</risdate><volume>43</volume><issue>4</issue><spage>31</spage><epage>32</epage><pages>31-32</pages><issn>0007-5027</issn><eissn>1943-7730</eissn><abstract>The abbreviated Wilson and Jungner criteria1 for an inheritable disorder to be considered for testing include an acceptable prevalence in the population, serious medical complications if not treated before symptoms arise, the potential for successful treatment, the availability of technology to screen hundreds of specimens daily, and cost favorability (ie, the cost of detection by screening is significantly less than a clinical diagnosis). Newborn screening for cystic fibrosis (CF) meets these requirements and has been included in the 30 core disorders, recommended by the US Secretary of Health and Human Services, for which all state newborn screening programs should screen.</abstract><cop>Chicago</cop><pub>Oxford University Press</pub><doi>10.1309/LM2AIVMAI9TR6JQI</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-5027 |
| ispartof | Laboratory medicine, 2012-05, Vol.43 (4), p.31-32 |
| issn | 0007-5027 1943-7730 |
| language | eng |
| recordid | cdi_proquest_journals_1020639451 |
| source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Babies Colleges & universities Committees Cystic fibrosis Deoxyribonucleic acid DNA Medical screening Mutation Newborn babies Public health Quality control |
| title | CLSI Announces Guidelines for Newborn Screening for Cystic Fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T01%3A58%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CLSI%20Announces%20Guidelines%20for%20Newborn%20Screening%20for%20Cystic%20Fibrosis&rft.jtitle=Laboratory%20medicine&rft.au=Hoffman,%20Gary%20L&rft.date=2012-05&rft.volume=43&rft.issue=4&rft.spage=31&rft.epage=32&rft.pages=31-32&rft.issn=0007-5027&rft.eissn=1943-7730&rft_id=info:doi/10.1309/LM2AIVMAI9TR6JQI&rft_dat=%3Cproquest_cross%3E2688712671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1020639451&rft_id=info:pmid/&rfr_iscdi=true |